BidaskClub Upgrades Agios Pharmaceuticals (AGIO) to Sell

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Wednesday.

A number of other equities research analysts have also recently commented on AGIO. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Royal Bank of Canada initiated coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 target price for the company. JPMorgan Chase & Co. reissued a “buy” rating and set a $76.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. SunTrust Banks reissued a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Finally, Credit Suisse Group increased their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $75.70.

Shares of Agios Pharmaceuticals (AGIO) opened at $59.82 on Wednesday. Agios Pharmaceuticals has a 52-week low of $39.24 and a 52-week high of $72.73. The firm has a market cap of $2,833.60, a P/E ratio of -9.54 and a beta of 1.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. During the same quarter in the prior year, the company earned ($1.63) EPS. The company’s revenue was up 26.4% compared to the same quarter last year. analysts predict that Agios Pharmaceuticals will post -6.59 earnings per share for the current year.

In other news, insider Scott Biller sold 2,146 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $67.23, for a total value of $144,275.58. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 3,838 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $59.37, for a total transaction of $227,862.06. Following the completion of the sale, the director now owns 80,851 shares in the company, valued at approximately $4,800,123.87. The disclosure for this sale can be found here. Insiders have sold a total of 127,746 shares of company stock worth $8,733,196 in the last 90 days. 5.43% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. QS Investors LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth $144,000. Cubist Systematic Strategies LLC increased its stake in shares of Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 3,123 shares during the period. Aperio Group LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth $206,000. Teacher Retirement System of Texas acquired a new stake in shares of Agios Pharmaceuticals in the third quarter worth $225,000. Finally, S&CO Inc. acquired a new stake in shares of Agios Pharmaceuticals in the third quarter worth $227,000. Hedge funds and other institutional investors own 93.79% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “BidaskClub Upgrades Agios Pharmaceuticals (AGIO) to Sell” was originally reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://weekherald.com/2017/12/27/bidaskclub-upgrades-agios-pharmaceuticals-agio-to-sell.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

BidaskClub Upgrades Agios Pharmaceuticals (AGIO) to Sell

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Wednesday.

A number of other equities research analysts have also recently commented on AGIO. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Royal Bank of Canada initiated coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 target price for the company. JPMorgan Chase & Co. reissued a “buy” rating and set a $76.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. SunTrust Banks reissued a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Finally, Credit Suisse Group increased their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $75.70.

Shares of Agios Pharmaceuticals (AGIO) opened at $59.82 on Wednesday. Agios Pharmaceuticals has a 52-week low of $39.24 and a 52-week high of $72.73. The firm has a market cap of $2,833.60, a P/E ratio of -9.54 and a beta of 1.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. During the same quarter in the prior year, the company earned ($1.63) EPS. The company’s revenue was up 26.4% compared to the same quarter last year. analysts predict that Agios Pharmaceuticals will post -6.59 earnings per share for the current year.

In other news, insider Scott Biller sold 2,146 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $67.23, for a total value of $144,275.58. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 3,838 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $59.37, for a total transaction of $227,862.06. Following the completion of the sale, the director now owns 80,851 shares in the company, valued at approximately $4,800,123.87. The disclosure for this sale can be found here. Insiders have sold a total of 127,746 shares of company stock worth $8,733,196 in the last 90 days. 5.43% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. QS Investors LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth $144,000. Cubist Systematic Strategies LLC increased its stake in shares of Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 3,123 shares during the period. Aperio Group LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth $206,000. Teacher Retirement System of Texas acquired a new stake in shares of Agios Pharmaceuticals in the third quarter worth $225,000. Finally, S&CO Inc. acquired a new stake in shares of Agios Pharmaceuticals in the third quarter worth $227,000. Hedge funds and other institutional investors own 93.79% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “BidaskClub Upgrades Agios Pharmaceuticals (AGIO) to Sell” was originally reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://weekherald.com/2017/12/27/bidaskclub-upgrades-agios-pharmaceuticals-agio-to-sell.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply